X0306 4 2020-09-01 0 0001674416 CRISPR Therapeutics AG CRSP 0001682017 Novak Rodger C/O CRISPR THERAPEUTICS, INC. 610 MAIN STREET CAMBRIDGE MA 02139 1 1 0 0 President Common Shares 2020-09-01 4 M 0 3933 14.00 A 651940 D Common Shares 2020-09-01 4 M 0 21067 14.43 A 673007 D Common Shares 2020-09-01 4 S 0 1406 91.54 D 671601 D Common Shares 2020-09-01 4 S 0 19754 92.59 D 651847 D Common Shares 2020-09-01 4 S 0 3840 93.19 D 648007 D Stock Option (Right to Buy) 14.00 2020-09-01 4 M 0 3933 0.00 D 2026-10-18 Common Shares 3933 111893 D Stock Option (Right to Buy) 14.43 2020-09-01 4 M 0 21067 0.00 D 2027-06-15 Common Shares 21067 215315 D The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.93 to $91.805, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.99 to $92.965, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.005 to $93.81, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. This option was granted on October 18, 2016 with respect to 200,000 Common Shares and originally vested in 48 equal monthly installments beginning October 31, 2016. Pursuant to Dr. Novak's amended and restated employment agreement with the Company, subject to his continued employment, beginning November 30, 2018, the remaining unvested options from this grant vest in equal monthly installments at the rate of 50% of the amounts originally scheduled to vest on any one vesting date, and the original vesting schedule was extended to reflect the amended schedule. This option was granted on June 15, 2017 with respect to 270,000 Common Shares and originally vested in 48 equal monthly installments commencing upon the grant date. Pursuant to Dr. Novak's amended and restated employment agreement with the Company, subject to his continued employment, beginning November 30, 2018, the remaining unvested options from this grant vest in equal monthly installments at the rate of 50% of the amounts originally scheduled to vest on any one vesting date, and the original vesting schedule was extended to reflect the amended schedule. /s/ Michael Esposito, attorney-in-fact 2020-09-03